What's Happening?
The National Institute for Health and Care Excellence (NICE) has issued new guidance allowing the use of the hormonal therapy abiraterone for men with high-risk localized or locally advanced prostate cancer
in England. This decision follows a campaign by patient groups, including Prostate Cancer UK, and is based on data from phase 3 studies showing that abiraterone, when added to standard androgen deprivation therapy, significantly reduces the risk of cancer recurrence and mortality. Previously, abiraterone was only available for advanced prostate cancer. The availability of generic versions has reduced the cost, making it more accessible. However, Northern Ireland remains the only UK region where this treatment is not available for early-stage patients.
Why It's Important?
This development is significant as it potentially saves the lives of approximately 3,000 men over the next five years by providing access to a life-extending treatment. The decision highlights the impact of advocacy and data-driven policy changes in healthcare. It also underscores the importance of equitable access to medical treatments across different regions. The reduced cost of abiraterone due to generic availability further emphasizes the role of cost-effectiveness in healthcare decision-making. This move may prompt further discussions on healthcare access disparities and the need for uniform treatment availability across the UK.
What's Next?
Prostate Cancer UK plans to continue advocating for access to abiraterone in Northern Ireland, aiming for uniform treatment availability across the UK. Additionally, the charity is pushing for widespread prostate cancer screening using PSA testing, despite recent government restrictions. The ongoing efforts may lead to further policy changes and increased awareness about prostate cancer treatment and screening options.
